Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CYTXZ - Cytori Therapeutics Inc Warrant 2017-28.05.20 on Cytori Therapeutics Series S


Previous close
0.0014
0.001   100.000%

Share volume: 0
Last Updated: Tue 23 Jul 2019 10:00:00 PM CEST
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%

N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
59%
Profitability 75%
Dept financing 25%
Liquidity 0%
Performance 65%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.00
P/E Ratio 
N/A
DAY RANGE
$0.00 - $0.00
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.18
52 WEEK CHANGE
-$100.00
MARKET CAP 
31.018 K
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$30,838
AVERAGE 30 VOLUME 
$33,252
Company detail
CEO: Marc H. Hedrick
Region: US
Website: http://www.cytori.com
Employees: 0
IPO year: -
Issue type:
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.

Recent news